Hello manoj kumar valluru,
Our friends from up North have done it again ! For one reason or another Calgary Canada seems to be the birthplace of a lot of interesting patents. Stem Cell Therapeutics, who you may remember, not only have patents on various hormones that activate endogenous stem cells, such as PACAP, Prolactin, and EPO, but are actually in Phase II clinical trials using such approaches in stroke. Last week another interesting Calgary company, Oncolytics, made news by being issued a patent (# 7,431,932) on the used of reovirus to selectively purge bone marrow cells of contaminating cancer cells. This is very interesting technology since reovirus possesses a great safety profile and already is in clinical trials by the company.
Other patents of interest, Novocell was issued #7,432,104 teaching how to grow ES cells on human feeder cells, Ian Wilmut recieved another patent on nuclear transfer, #7,432,415, and a new method of stimulating hematopoietic stem cells post-chemo was revealed, #7,432,236, through the administration of the peptide vasostatin.
On the academic publication front, a neat paper came out last week showing that it is possible to target stem cells to apoptotic cells through conjugation of Annexin-V to stem cells.
|
|
|
|
Thanks again for your help in supporting StemCellPatents.com.
RMSC 2008 World Congress
The 3rd Annual Stem Cells World Congress
The Stem Cell Meeting
Media Partnerships
We welcome your comments and suggestions! Tell us here.